Literature DB >> 565227

Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes.

R I Handin, T P Stossel.   

Abstract

Patients with idiopathic thrombocytopenic purpura (ITP), a disorder in which antibody coated platelets are cleared from the circulation by phagocytic cells, are often treated with glucocorticoids. The effect of corticosteroids on the recognition and ingestion of sensitized platelets by phagocytes can be quantified in these patients and compared to changes in platelet levels. Six patients with ITP were treated with 96 mg daily of methylprednisolone for 5 days. This treatment raised their platelet count and simultaneously decreased the ability of their granulocytes to phagocytize antibody-coated platelets and C3-coated paraffin oil droplets. Corticosteroid treatment did not affect the binding of antibody to platelets or the quantity of antibody in the patients' serum. The ingestion defect was present in isolated, washed leukocytes and persisted for 3-5 days after the corticosteroids were discontinued. Granulocytes and purified monocytes obtained from patients with other medical disorders receiving corticosteroids also ingested paraffin oil droplets and opsonized platelets at a slower rate. These studies provide direct evidence that corticosteroids induce a generalized phagocytic defect and that this may be the mechanism by which corticosteroids raise the platelet count in patients with ITP.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565227

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

2.  High doses of gamma globulin and methylprednisolone therapy for idiopathic thrombocytopenic purpura in children.

Authors:  T Hara; S Miyazaki; N Yoshida; N Goya
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

Review 3.  The role of complement in immune clearance of blood cells.

Authors:  U E Nydegger; M D Kazatchkine
Journal:  Springer Semin Immunopathol       Date:  1983

4.  In vitro effect of hydrocortisone on the attachment and ingestion phases of immunoglobulin G- and complement component 3b-mediated phagocytosis by human neutrophils.

Authors:  J Forslid; J Hed
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

5.  Influence of dexamethasone on some cellular aspects of the immune system in cats.

Authors:  M Hoffmann-Jagielska; A Winnicka; D Jagielski; R Lechowski
Journal:  Vet Res Commun       Date:  2003-12       Impact factor: 2.459

6.  Neutrophil-mediated antibody-dependent cellular cytotoxicity against erythrocytes. Mechanisms of target cell destruction.

Authors:  F Dallegri; F Patrone; G Holm; G Gahrton; C Sacchetti
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

7.  Effect of corticosteroids on the production of superoxide and hydrogen peroxide and the appearance of chemiluminescence by phagocytosing polymorphonuclear leukocytes.

Authors:  P H Levine; J C Hardin; K L Scoon; N I Krinsky
Journal:  Inflammation       Date:  1981-03       Impact factor: 4.092

Review 8.  Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT).

Authors:  Nadia Gabarin; Donald M Arnold; Ishac Nazy; Theodore E Warkentin
Journal:  Semin Hematol       Date:  2022-03-07       Impact factor: 3.754

9.  Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration.

Authors:  Leo Nicolai; Alexander Leunig; Kami Pekayvaz; Max Esefeld; Afra Anjum; Justina Rath; Eva Riedlinger; Vincent Ehreiser; Magdalena Mader; Luke Eivers; Marie-Louise Hoffknecht; Zhe Zhang; Daniela Kugelmann; Dario Rossaro; Raphael Escaig; Rainer Kaiser; Vivien Polewka; Anna Titova; Tobias Petzold; Karsten Spiekermann; Matteo Iannacone; Thomas Thiele; Andreas Greinacher; Konstantin Stark; Steffen Massberg
Journal:  Blood       Date:  2022-08-04       Impact factor: 25.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.